Coronary artery disease (CAD) was associated with a 35% increased risk of a prostate cancer (PCa) diagnosis among the 6,390 men taking part in the REDUCE trial, which evaluated whether dutasteride reduced PCa risk. Overall, 547 enrollees (8.6%) had a history of CAD.
Compared with men who had no heart disease, those with CAD were 24% more likely to be diagnosed with PCa two years into the REDUCE trial and 74% more likely four years into the study, Stephen J. Freedland, MD, and colleagues reported in Cancer Epidemiology, Biomarkers & Prevention.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.